Axa’s Portola Pharmaceuticals, Inc. PTLA Stock Holding History

Axa’s Portfolio PTLA Stock Details PTLA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-12,900	Closed	-$421K	–	1440
2018 Q1	$421K	Sell	12,900 -67,700	-84%	-$2.97M	﹤0.01%	1199
2017 Q4	$3.92M	Buy	80,600 +19,600	+32%	+$991K	0.02%	714
2017 Q3	$3.3M	Buy	+61,000	New	+$3.58M	0.01%	730
2016 Q2	–	Sell	-226,427	Closed	-$4.62M	–	1436
2016 Q1	$4.62M	Sell	226,427 -3,658	-2%	-$116K	0.02%	582
2015 Q4	$11.8M	Sell	230,085 -4,836	-2%	-$234K	0.05%	345
2015 Q3	$10M	Sell	234,921 -4,970	-2%	-$240K	0.04%	381
2015 Q2	$10.9M	Hold	239,891	–	–	0.04%	401
2015 Q1	$9.11M	Sell	239,891 -646	-0.3%	-$22.2K	0.04%	423
2014 Q4	$6.81M	Sell	240,537 -18,613	-7%	-$517K	0.03%	478
2014 Q3	$6.55M	Sell	259,150 -1,664	-0.6%	-$43.8K	0.03%	475
2014 Q2	$7.61M	Sell	260,814 -7,410	-3%	-$179K	0.03%	450
2014 Q1	$6.95M	Buy	+268,224	New	+$7.16M	0.03%	462

Other funds holding PTLA

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

PHS

PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

CCM

Cadian Capital Management New York $821M AUM 14.36% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

ZCI

Zevenbergen Capital Investments Edmonds, Washington $4.38B AUM 56.68% 1-Year Est. Return

Axa's PTLA Position: Q2 2018 in Review

Axa sold out of Portola Pharmaceuticals, Inc. (PTLA) in Q2 2018, closing a stake of 12,900 shares — an estimated $421K sold.

Axa first reported a position in PTLA in Q1 2014 and held it in 12 quarters. The position peaked at $11.8M in Q4 2015. 204 funds tracked by Wall St. Rank hold PTLA as of Q2 2018.

Axa reported no remaining Portola Pharmaceuticals, Inc. position as of Q2 2018 after selling out during the quarter.
Axa sold 12,900 Portola Pharmaceuticals, Inc. shares in Q2 2018, an estimated $421K.
Axa first reported a position in Portola Pharmaceuticals, Inc. in Q1 2014 and held it in 12 quarters.
Axa's Portola Pharmaceuticals, Inc. position peaked at $11.8M in Q4 2015.
204 funds tracked by Wall St. Rank held Portola Pharmaceuticals, Inc. as of Q2 2018.

Based on Axa's 13F filing for Q2 2018, filed 13 Aug 2018.